Chemotherapy and immunomodulation: From immunogenic chemotherapies to novel therapeutic strategies

Future Oncology

Volumn 9, Issue 4, 2013, Pages 469-472

  Ghiringhelli, Francois ^a,b,c   Apetoh, Lionel ^a,b,c  

^a boulevard Jeanne d'Arc   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

5 fluorouracil; anticancer immunity; chemoimmunotherapy; immunosuppression; inflammasome; myeloid derived suppressor cell

Indexed keywords

CALRETICULIN; FLUDARABINE; FLUOROURACIL; INTERLEUKIN 17; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR FOXP3;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; DRUG EFFICACY; HEMATOPOIETIC CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOMODULATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TUMOR GROWTH;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DEATH; CYCLOPHOSPHAMIDE; FEMALE; FLUOROURACIL; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; T-LYMPHOCYTES, REGULATORY;

EID: 84875944680     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.207     Document Type: Review

References (20)

1. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8), 3052-3061 (2010).
2. Bruchard M, Mignot G, Derangere V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 19(1), 57-64 (2013).
3. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312(13), 818-822 (1985). (Pubitemid 15104774)
4. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92(4), 1165-1171 (1998). (Pubitemid 28369029)
5. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends Mol. Med. 14(4), 141-151 (2008).
6. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13(9), 1050-1059 (2007). (Pubitemid 47517504)
7. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13(1), 54-61 (2007). (Pubitemid 46067386)
8. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1b-dependent adaptive immunity against tumors. Nat. Med. 15(10), 1170-1178 (2009).
9. Apetoh L, Vegran F, Ladoire S, Ghiringhelli F. Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies. Curr. Mol. Med. 11(5), 365-372 (2011).
10. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56(5), 641-648 (2007). (Pubitemid 46348738)
11. Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response. J. Exp. Med. 201(10), 1591-1602 (2005). (Pubitemid 40723662)
12. Kasprowicz DJ, Droin N, Soper DM, Ramsdell F, Green DR, Ziegler SF. Dynamic regulation of FoxP3 expression controls the balance between CD4+ T cell activation and cell death. Eur. J. Immunol. 35(12), 3424-3432 (2005). (Pubitemid 43025523)
13. Roux S, Apetoh L, Chalmin F, et al. CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer. J. Clin. Invest. 118(11), 3751-3761 (2008).
14. Zhao J, Cao Y, Lei Z, Yang Z, Zhang B, Huang B. Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels. Cancer Res. 70(12), 4850-4858 (2010).
15. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J. Exp. Med. 206(7), 1457-1464 (2009).
16. Fass L, Fefer A. Studies of adoptive chemoimmunotherapy of a Friend virus-induced lymphoma. Cancer Res. 32(5), 997-1001 (1972).
17. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8(1), 59-73 (2008).
18. Menger L, Vacchelli E, Adjemian S, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci. Transl. Med. 4(143), 143ra199 (2012).
19. Ding ZC, Huang L, Blazar BR, et al. Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood 120(11), 2229-2239 (2012).
20. Lake RA, Robinson BW. Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer 5(5), 397-405 (2005). (Pubitemid 40637831)